Immune Protective Mechanism of Qingying Jiebiao Heji on Influenza

SUN Xi-wen1; LV Cui-xiao2; ZHANG Miao1; SUN Xi-tao3; YU Bin1; ZHANG Ge1

doi:10.13422/j.cnki.syfjx.2010.11.051

您当前的位置：

首页 >

文章列表页 >

Immune Protective Mechanism of Qingying Jiebiao Heji on Influenza

更新时间：2024-09-23

- Immune Protective Mechanism of Qingying Jiebiao Heji on Influenza
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 16, Issue 11, Pages: 161-164(2010)
- 作者机构：
  
  1. 暨南大学医学院
  2. 山东中医药大学
  3. 喀什师范学院
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2010.11.051
  CLC： R285.5
- Published：2010
- 稿件说明：
移动端阅览
[1]孙喜稳,吕翠霞,张淼,孙喜涛,余斌,张歌.清营解表合剂防治流感免疫调节机制的研究[J].中国实验方剂学杂志,2010,16(11):161-164.

SUN Xi-wen1, LV Cui-xiao2, ZHANG Miao1, et al. Immune Protective Mechanism of Qingying Jiebiao Heji on Influenza[J]. Chinese journal of experimental traditional medical formulae, 2010, 16(11): 161-164.
[1]孙喜稳,吕翠霞,张淼,孙喜涛,余斌,张歌.清营解表合剂防治流感免疫调节机制的研究[J].中国实验方剂学杂志,2010,16(11):161-164. DOI： 10.13422/j.cnki.syfjx.2010.11.051.

SUN Xi-wen1, LV Cui-xiao2, ZHANG Miao1, et al. Immune Protective Mechanism of Qingying Jiebiao Heji on Influenza[J]. Chinese journal of experimental traditional medical formulae, 2010, 16(11): 161-164. DOI： 10.13422/j.cnki.syfjx.2010.11.051.

摘要

目的:探讨清营解表合剂对流感病毒A/PR/8/H1N1感染小鼠免疫保护的作用机制。方法:以亚洲甲型鼠肺适应株A/PR/8/H1N1流感病毒小鼠滴鼻

建立感染模型。分别给予病毒唑、清营解表合剂

计算死亡保护率、延长生命率;测定小鼠胸腺指数和脾脏指数;流式细胞术检测小鼠外周血特异性细胞因子Th1（γ-干扰素

IFN-γ）/Th2（白介素-10

IL-10）表达水平。结果:清营解表合剂组小鼠死亡保护率和生命延长率分别为52.94%和37.64%

小鼠脾脏指数和胸腺指数明显提高。感染后小鼠外周血细胞的Th1型反应弱势表达

Th2细胞因子优势表达

Th1（IFN-γ）/Th2（IL-10）比值明显降低

Th1/Th2表达向Th2偏移。清营解表合剂组Th1细胞因子水平显著升高

且向空白组正常水平方向漂移。结论:清营解表合剂对感染小鼠具有明显的死亡保护作用

能够逆转流感病毒感染小鼠外周血因子Th1向Th2漂移的作用

通过免疫调节作用防治流行性感冒。

Abstract

Objective:To study the immune protective mechanism of Qingying Jiebiao Heji on A/PR/8 / H1N1 virus infected mice.Method:The influenza model in mice was established through dropping A /PR /8 /H1N1 virus into the nose of Kunming mice.Ribavirin and Qingying Jiebiao Heji were given to the infected mice respective-ly

then death protection and life prolongation were determined;thymus index and spleen index were observed;Th1（IFN-γ） /Th2（IL-10） expression in peripheral blood was measured by flow cytometry.Result:After being infec-ted

the death protection rate and life prolongation rate of Qingying Jiebiao Heji were 52.94% and 37.64% accord-ingly

the thymus index and spleen index were improved apparently.Th1cytokine IFN-γ attenuated and Th2cytokine IL-10 dominantly expressed.The expression of Th1（IFN-γ） /Th2（IL-10） was remarkably depressed and adjusted

Th2 expression of Qingying Jiebiao Heji group was markedly strengthened and Th1 / Th2 drifted towards the normal level.Conclusion:Qingying Jiebiao Heji has the effect of death protection on the A /PR /8 /H1N1 virus infected mice

it also can reverse its peripheral blood cytokine Th1drifting to Th2

and prevent influenza through immune reg-ulation.

关键词

Keywords

references

Views

152

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Immune Protective Mechanism of Qingying Jiebiao Heji on Influenza

Jiebiao Qingli Decoction Regulates TLR7/MAPK/NF-κB Pathway to Prevent and Treat Pneumonia Induced by IAV Infection

Oral Chinese Patent Medicines for Influenza： A Scoping Review of Clinical Evidence

Effect of Shukang Pingchuan Capsule on IFN-γ,IL-4,IL-5 and IFN-γ/IL-4 in Asthmatic Rats

Related Author

ZHANG Ge

YU Bin

SUN Xi-tao

ZHANG Miao

LV Cui-xia

SUN Xi-wen

ZHANG Hongchun

CHAO Yan

Related Institution

Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences

Shenzhen Bao'an Authentic Traditional Chinese Medicine Therapy Hospital

Shenzhen Nanshan District Hospital of Traditional Chinese Medicine

Beijing Oriental Yunjia Pharmaceuticals Co. Ltd.

Clinical Research Center for Respiratory Diseases，China-Japan Friendship Hospital

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰